--- title: USJCMSP 2024 EID --- - [Grants & Procurement](https://www.crdfglobal.org/grants-procurement/) - [Contact Us](https://www.crdfglobal.org/contact-us/) [Facebook](https://www.facebook.com/CRDFGlobal) [Instagram](https://www.instagram.com/crdfglobal/)[Linkedin](https://www.linkedin.com/company/crdf-global) [![](https://insights.crdfglobal.org/hubfs/crdf-logo.svg)](https://crdfglobal.org/) - WHO WE ARE #### [Our Story](https://crdfglobal.org/our-story/) #### [Mission, Vision & Values](https://crdfglobal.org/mission-vision-values/) #### [Leadership](https://crdfglobal.org/leadership) #### [Our Experts](https://crdfglobal.org/experts) #### [Clients & Partners](https://crdfglobal.org/partners) ![Who we are mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/06/who-we-are-menu.jpg) More than 30 years advancing international security, technology, and economic progress in over 120 countries. - WHAT WE DO #### [Chemical, Biological & Nuclear Security](https://www.crdfglobal.org/what-we-do/cbrne-security-counterproliferation/) #### [Cybersecurity & Digital Resilience](https://www.crdfglobal.org/what-we-do/cybersecurity/) #### [Research, Data & Emerging Technology Security](https://www.crdfglobal.org/what-we-do/research-data-and-technology-security/) #### [Security Cooperation & Exchanges](https://www.crdfglobal.org/what-we-do/international-exchanges/) #### [Border Security & Strategic Trade Controls](https://www.crdfglobal.org/what-we-do/strategic-trade-border-security/) #### [Health Security and Research](https://www.crdfglobal.org/what-we-do/global-health/) ![What we do mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/07/MegaMenu_Website_Images_Ratios_SizesWhat-We-Do-Mega-Menu.png) Addressing evolving security and prosperity challenges through strategically tailored solutions. - HOW WE DELIVER ### CORE CAPABILITIES #### [Travel & Logistics](https://crdfglobal.org/capabilities/travel-logistics/) #### [Specialized Equipment Procurement](https://crdfglobal.org/capabilities/specialized-equipment-procurement/) #### [Technical & Professional Trainings](https://crdfglobal.org/capabilities/technical-and-professional-trainings/) #### [Fellowships & Exchanges](https://crdfglobal.org/capabilities/fellowships-and-exchanges/) #### [Grants & Research Competitions](https://crdfglobal.org/capabilities/grants-research-competitions/) #### [Security Strengthening](https://crdfglobal.org/capabilities/security-strengthening/) ### INTEGRATED SOLUTIONS #### [Program Design and Management](https://crdfglobal.org/integrated-solutions/program-design-and-management/) #### [Quality Framework](https://crdfglobal.org/integrated-solutions/quality-framework/) #### [Monitoring, Evaluation and Learning](https://crdfglobal.org/integrated-solutions/monitoring-evaluation-and-learning/) #### [Remote Training & Learning](https://crdfglobal.org/integrated-solutions/remote-training-and-learning/) ![How we deliver mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/01/how-we-deliver-menu-v2.jpg) Recognized leader in global program delivery, combining technical expertise with flexible, locally driven solutions. - [WHERE WE WORK](https://crdfglobal.org/where-we-work/) - [NEWS & INSIGHTS](https://www.crdfglobal.org/news/) - [CAREERS](https://crdfglobal.org/careers/) - [\> Home](https://insights.crdfglobal.org/usjcmspeid2024) - [\> General Registration](https://insights.crdfglobal.org/usjcmspeid2024-1) - [\> Speaker Registration](https://insights.crdfglobal.org/usjcmspeid2024-1-1) - [\> Plenary Agenda](https://insights.crdfglobal.org/usjcmspeid2024-agenda) - [\> Panel Agendas](https://insights.crdfglobal.org/usjcmspeid2024panels) - [\> Travel Information](https://insights.crdfglobal.org/usjcmspeid2024-travel) - [\> IDRIC Symposium](https://idric.kr/) - [\> Abstract eBooks](https://insights.crdfglobal.org/usjcmspeid2024_ebooks) --- ![USJCMSP logo5 title](https://insights.crdfglobal.org/hs-fs/hubfs/USJCMSP%20logo5%20title.jpg?width=300&height=179&name=USJCMSP%20logo5%20title.jpg "USJCMSP logo5 title") ## The Joint 24th International Conference on Emerging Infectious Diseases in the Pacific Rim of the U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) in collaboration with the 2nd International Symposium for Infectious Diseases Research Institutes Cooperation (IDRIC) ![logo1 (003)](https://insights.crdfglobal.org/hs-fs/hubfs/logo1%20(003).png?width=125&height=125&name=logo1%20(003).png "logo1 (003)") ![NIH\_Master\_Logo\_Vertical\_2Color-PNG (002)](https://insights.crdfglobal.org/hs-fs/hubfs/NIH_Master_Logo_Vertical_2Color-PNG%20(002).png?width=125&height=110&name=NIH_Master_Logo_Vertical_2Color-PNG%20(002).png "NIH_Master_Logo_Vertical_2Color-PNG (002)") ![KDCA\_KNIH\_KNIID LOGO change](https://insights.crdfglobal.org/hs-fs/hubfs/KDCA_KNIH_KNIID%20LOGO%20change.jpg?width=350&height=58&name=KDCA_KNIH_KNIID%20LOGO%20change.jpg "KDCA_KNIH_KNIID LOGO change") ![IVI\_logo (002)-1](https://insights.crdfglobal.org/hs-fs/hubfs/IVI_logo%20(002)-1.png?width=250&name=IVI_logo%20(002)-1.png "IVI_logo (002)-1") Disclaimer: The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. --- ### Plenary Agenda ###### Tuesday|5 March 2024 | DAY ONE Location: Grand Ballroom II & III \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 7:00-8:00 | Registration 8:00-8:30 | Welcome Remarks - Masters of Ceremony - Speakers - Dr. Youngmee Jee - Commissioner, Korea Disease Control and Prevention Agency - Mr. Taisuke Mibae - Minister and Deputy chief of Mission, Embassy of Japan - Mr. Andrew Herrup, Minister Counselor for Economic Affairs, Embassy of the United States of America - Dr. Hiroshi Kiyono - Distinguished Professor, Future Medicine Education and Research Organization, Chiba University/Department of Human Mucosal Vaccinology, Chiba University Hospital - Japan / Japanese Delegation Chair, USJCMSP - Dr. Diane E. Griffin - University Distinguished Service Professor, Johns Hopkins Bloomberg School of Public Health, USA - U.S Delegation Chair, USJCMSP 8:30-9:00 | Shimao-Takeda Lectureship - Introduced by Dr. Hiroshi Kiyono - Dr. Yoshihiro Kawaoka - The University of Tokyo / National Center for Global Health and Medicine / University of Wisconsin School of Veterinary Medicine 9:00-9:30 | La Montagne-Heilman Lectureship - Introduced by Dr. Diane E Griffin - Dr. Daved Fremont - Washington University in St. Louis \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 9:30-9:45 | Coffee Break  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION ONE: AI/Data Science-Based Prediction of Emerging Infection *Moderators: Dr. Kei Sato - The University of Tokyo & Dr. Richard Kuhn, Purdue University* *Rapporteurs: Dr. Conrad Mallia, NIAID*  9:45-10:05 | Real-time causal inference of COVID-19 interventions using counterfactual reproduction number | Dr. Hiroshi Nishiura - Kyoto University 10:05-10:10 | Q&A 10:10-10:30 | Evolution of SARS-CoV-2: Now and Then | Dr. Kei Sato - University of Tokyo 10:30-10:35 | Q&A 10:35-10:55 | Design of New Protein Functions Using Deep Learning | Dr. David Baker - University of Washington - Virtual 10:55-11:00 | Q&A 11:00-11:20 | Contributions to public health policies through data-driven mathematical modeling during the COVID-19 pandemic and future roles in this field | Dr. Eunok Jung - Konkuk University 11:20-11:25 | Q&A 11:25-11:45 | Data Science-based Prediction of Emerging Infections, with SARS-CoV-2 as an Example | Dr. Bette Korber - New Mexico Consortium - Virtual 11:45-11:50 | Q&A \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 12:00-13:30 | Lunch break and Poster Session \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION TWO: Vaccine Science and Technology *Moderators: Dr. Ken J. Ishii - The University of Tokyo & Dr. Woo Joo Kim - Korea University* *Rapporteurs: Dr. Hideki Ueno - Kyoto University & Dr. Erik Stemmy, NIAID, USA* 13:30-13:50 | Department of Bio-medical Science and Engineering, Konkuk University, Seoul, Republic of Korea | Dr. Young Bong Kim - Konkuk University 13:50-13:55 | Q&A 13:55-14:15 | Development of vaccines based on a replication-incompetent Ebola virus | Dr. Tokiko Watanabe - Osaka University  14:15-14:20 | Q&A 14:20-14:40 | Integrated Organ Immunity: A Path to a Universal Vaccine | Dr. Bali Pulendran - Stanford University 14:40-14:45 | Q&A 14:45-15:05 | Flagellin: A Versatile Engineerable Mucosal Vaccine Adjuvant | Dr. Joon Rhee - Chonnam National University Medical School 15:05-15:10 | Q&A 15:10-15:30 | From Need to Impact: Cholera Vaccine Development at IVI | Dr. Jerome Kim - International Vaccine Institute 15:30-15:35 | Q&A \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 15:35-15:50 |Break  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION THREE: Broad Immunity Against Pathogens *Moderators: Dr. Tatsuya Kanto - National Center for Global Health and Medicine* *Rapporteurs: Dr. Masanori Isogawa - National Institute of Infectious Diseases & Conrad Mallia - National Institute of Allergy and Infectious Diseases* 15:50-16:10 | Global vaccinations and the antipoverty vaccines science vs antiscience | Dr. Peter Hotez - Baylor College of Medicine - Virtual  16:10-16:15 | Q&A 16:15-16:35 | Involvement of phospholipase A2 group 4C induced by hepatitis C virus infection in hepatic lipid accumulation | Dr. Tadaki Suzuki - National Institute of Infectious Diseases 16:35-16:40 | Q&A 16:40-17:00 | Rotavirus replication and pathogenesis | Dr. Takeshi Kobayashi - Osaka University  17:00-17:05 | Q&A 17:05-17:25 | What makes an effective live-attenuated vaccine? New insights into the innate cellular response to yellow fever virus 17D (YFV-17D) | Dr. Sonja M. Best - National Institute of Allergy and Infectious Diseases 17:25-17:30 | Q&A 17:30-17:50 | Functional characteristics of SARS-CoV-2-specific memory CD8+ T cells | Eui-Cheol Shin - Korea Advance Institute of Science and Technology 17:50-17:55 | Q&A 17:55-18:00 | Announcements  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ ###### Wednesday | 6 March 2024 | DAY TWO \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION FOUR: Epidemiology and Surveillance *Moderators: Dr. Thomas Hope - Northwestern University & Dr. Mo-Ran Ki, National Cancer Center*  *Rapporteurs: Dr. Erik Stemmy - National Institute of Allergy and Infectious Diseases & Dr. Karl Salzwedel, National Institute of Allergy and Infectious Diseases* 8:00-8:20 | Statistical genetics elucidates biology and medicine of infectious diseases | **Dr. Yukinori Okada** - Osaka University 8:20-8:25 | Q&A 8:25-8:45 | Modeling clade I mpox lesion transition dynamics A retrospective analysis of clinical data in DRC | **Dr. Shingo Iwami** - Nagoya University 8:45-8:50 | Q&A 8:50-9:10 | Pandemic Preparedness — The PREMISE Program | **Dr. Danny Douek** - National Institiute of Allergy and Infectious Diseases 9:10-9:15 | Q&A 9:15-9:35 | Rapid Real-World Evidence Generation using South Korea's Database in the COVID-19 era | **Dr. Jae-Hun Jung** - Gachon University 9:35-9:40 | Q&A 9:40-10:00 | Mpox | **Dr. Anne Rimoin** - University of California, Los Angeles (Virtual) 10:00-10:05 | Q&A \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 10:05-10:20 | Coffee Break  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION FIVE: Factors Affecting Virus Emergence and Expansion *Moderators: Dr. Akira Nishizono - Oita University & Dr. Jorge Vidal - University of Mississippi* *Rapporteurs: Dr. Masaya Sugiyama - National Center for Global Health and Medicine & Dr. Eun-Chung Park - National Institute of Allergy and Infectious Diseases* 10:20-10:40 | Understanding the molecular mechanism of membrane dynamics-associated Ebola virus particle formation | Dr. Asuka Nanbo | Nagasaki University 10:40-10:45 | Q&A 10:45-11:05 | High exposure to Bas-Congo virus among Mangala residents 13 years after the Bas-Congo virus-associated acute hemorrhagic fever outbreak in the Democratic Republic of the Congo | Dr. Ayato Takada - Hokkaido University  11:05-11:10 | Q&A 11:10-11:30 | Severe Fever with Thrombocytopenia Syndrome (SFTS) in South | Dr. Sang Won Park - Seoul National University  11:30-11:35 | Q&A 11:35-11:55 | Factors driving the emerging bat zoonotic virus spillover | Dr. Linfa Wang - Duke-NUS Medical School - Virtual 11:55-12:00 | Q&A 12:00-12:20 | Polymicrobial Interactions Operative During Pathogen Transmission | Dr. Jason Rosch - St. Jude Children's Research Hospital 12:20-12:25 | Q&A \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 12:25-14:00 | Lunch Break and Poster Session \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION SIX: Strategies for Virus Elimination  *Moderators: Dr. Takaori-Kondo Akifumi - Kyoto University Hospital & Dr. Don-Gun Lee - The Catholic University of Korea* *Rapporteurs: Dr. Karl Salzwedel - National Institutes of Allergy and Infectious Diseases & Dr. Eun-Chung Park - National Institute of Allergy and Infectious Diseases* 14:00-14:20 | Strategies for HCV elimination in Japan: Achievement and challenges assessed by performance indicators. | Dr. Tetsuya Kanto - National Center for Global Health and Medicine  14:20-14:25 | Q&A 14:25-14:45 | Evasion of APOBEC1-mediated Intrinsic Immunity by a Herpesvirus Uracil DNA Glycosylase Is a Determinant of Viral Encephalitis | Dr. Yasushi Kawaguchi - The University of Tokyo 14:45-14:50 | Q&A 14:40-15:10 | Current Landscape and National Strategies for Viral Hepatitis in South Korea | Dr. Sook-Hyang Jeong - Seoul National University Bundang Hospital 15:10-15:15 | Q&A 15:15-15:35 | Sustaining measles and rubella elimination and poliomyelitis eradication status in the Republic of Korea | Dr. Jin Gwack - Jeonbuk National University  15:35-15:40 | Q&A \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 15:40-15:55 | Break  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION SEVEN: Clinical Management  *Moderators: Dr. Yohei Doi - Fujita Health University + University of Pittsburgh School of Medicine & Dr. Hee-Chang Jang, National Institute of Infectious Diseases* *Rapporteurs: Dr. Marie Ricciardone - National Cancer Institute* 15:55-16:15 | Emergency Preparedness in Clinical Laboratories: Lessons Learned from COVID-19 | Dr. Miki Nagao - Kyoto University 16:15-16:20 | Q&A 16:20-16:40 | COVID-19 clinical trials in Japan | Dr. Yohei Doi - Fujita Health University and University of Pittsburgh School of Medicine 16:40-16:45 | Q&A 16:45-17:05 | Respiratory syncytial virus infection and management in high-risk patients | Dr. YaeJean Kim - Samsung Medical Center in Seoul 17:05-17:10 | Q&A 17:10-17:30 | Viral shedding kinetics in patients with SARS-CoV-2 infection | Dr. Sung-Han Kim - Asan Medical Center 17:30-17:35 | Q&A 17:35-17:55 | Advancing Clinical Management of Influenza Through AI-Driven Diagnostics and Prediction | Dr. Kuan-Fu Chen - Chang Gung University 17:55-18:00 | Q&A 18:00-18:05 | Closing Remarks \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ ###### Thursday| 7 March 2024 | DAY THREE \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Panel Sessions: - HIV/AIDS Panel - Acute Respiratory Infections Panel - Cancer Panel - Hepatitis Panel - [Click here to view the Hepatitis Panel Draft Agenda.](https://insights.crdfglobal.org/usjcmspeid2024-agenda-hepatitis?hsLang=en) - Immunology Board - [Click here to view the Immunology Panel Draft Agenda.](https://insights.crdfglobal.org/usjcmspeid2024-immunology?hsLang=en) - Viral Diseases Panel - [Click here to view the Viral Diseases Draft Panel Agenda.](https://insights.crdfglobal.org/usjcmspeid2024-agenda-viraldiseases?hsLang=en) ###### Friday| 8 March 2024 | DAY FOUR \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Panel Sessions: - HIV/AIDS Panel - Cancer Panel - Hepatitis Panel - [Click here to view the Hepatitis Panel Draft Agenda.](https://insights.crdfglobal.org/usjcmspeid2024-agenda-hepatitis?hsLang=en) - Viral Diseases Panel - [Click here to view the Viral Diseases Draft Panel Agenda.](https://insights.crdfglobal.org/usjcmspeid2024-agenda-viraldiseases?hsLang=en) --- ## If you have any questions or technical issues please contact Annie King, [aking@crdfglobal.org](mailto:aking@crdfglobal.org) ![](https://www.crdfglobal.org/wp-content/uploads/2021/12/crdf-logo-white.svg) #### Advancing U.S. national security by mitigating threats and enhancing opportunities through technology, innovation, and collaboration. ### Let us know how we can help you reach your goals [Facebook Facebook](https://www.facebook.com/CRDFGlobal) [Twitter](https://twitter.com/CRDFGlobal) [Instagram Instagram](https://www.instagram.com/crdfglobal/) [Linkedin Linkedin](https://www.linkedin.com/company/crdf-global)[Contact Us](https://insights.crdfglobal.org/contact-us?hsLang=en) - WHO WE ARE - [Our Story](https://crdfglobal.org/our-story/) - [Mission, Vision & Values](https://crdfglobal.org/mission-vision-values/) - [Leadership](https://insights.crdfglobal.org/leadership?hsLang=en) - [Our Experts](https://insights.crdfglobal.org/experts?hsLang=en) - [Partners](https://insights.crdfglobal.org/partners?hsLang=en) - WHAT WE DO - [Chemical, Biological & Nuclear Security](https://www.crdfglobal.org/what-we-do/cbrne-security-counterproliferation/) - [Cybersecurity & Digital Resilience](https://www.crdfglobal.org/what-we-do/cybersecurity/) - [Research, Data & Emerging Technology Security](https://www.crdfglobal.org/what-we-do/research-data-and-technology-security/) - [Security Cooperation & Exchanges](https://www.crdfglobal.org/what-we-do/international-exchanges/) - [Border Security & Strategic Trade Controls](https://www.crdfglobal.org/what-we-do/strategic-trade-border-security/) - [Health Security & Research](https://www.crdfglobal.org/what-we-do/global-health/) - HOW WE DELIVER - [Travel & Logistics](https://www.crdfglobal.org/capabilities/travel-logistics/) - [Security Strengthening](https://www.crdfglobal.org/capabilities/security-strengthening/) - [Fellowships & Exchanges](https://www.crdfglobal.org/capabilities/fellowships-and-exchanges/) - [Grants & Research Competitions](https://www.crdfglobal.org/capabilities/grants-research-competitions/) - [Technical & Professional Training](https://www.crdfglobal.org/capabilities/technical-and-professional-trainings/) - [Specialized Equipment Procurement](https://www.crdfglobal.org/capabilities/specialized-equipment-procurement/) - [Program Design and Management](https://www.crdfglobal.org/integrated-solutions/program-design-and-management/) - [Monitoring, Evaluation and Learning](https://www.crdfglobal.org/integrated-solutions/monitoring-evaluation-and-learning/) - [Remote Training & Learning](https://www.crdfglobal.org/integrated-solutions/remote-training-and-learning/) - [Quality Framework](https://www.crdfglobal.org/integrated-solutions/quality-framework/) - COLLABORATE - [Become a Partner](https://www.crdfglobal.org/become-a-partner/) - [Grants & Procurement](https://www.crdfglobal.org/grants-procurement/) - [Procurement & RFPs](https://insights.crdfglobal.org/rfp?hsLang=en) - [Funding & Grants](https://insights.crdfglobal.org/funding-opportunities?hsLang=en) - [WHERE WE WORK](https://crdfglobal.org/where-we-work/) - [NEWS & INSIGHTS](https://www.crdfglobal.org/news/) - [CAREERS](https://www.crdfglobal.org/careers/) [Privacy Policy](https://www.crdfglobal.org/data-privacy-policy/)    [Code of Conduct](https://www.crdfglobal.org/participant-code-of-conduct/) © 2026 CRDF Global - All rights reserved